We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

A bit far-sighted

7 April 2008 By Jeffrey Goldfarb

The Swiss drugmaker is paying $11bn now for 25% of Nestlé’s fastgrowing eyecare business and $28bn in two years time for a further 52%. Novartis is getting the initial stake at a discount to Alcon’s share price, but this way, any synergies will take years to come through.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)